'Why Hope' Artist

The Goal of the HOPE Study

ViiV Healthcare initiated a market research study—The HIV Optimized Patient Experience (HOPE) Study—to understand how patients and healthcare professionals (HCPs) prioritize treatment goals and how this impacts patients' experiences with treatment.1


In part, this is because there is a recognition that HIV treatment is evolving at a rapid pace, helping patients achieve viral suppression. Both the Department of Health and Human Services (DHHS) and the World Health Organization (WHO) guidelines reflect this progress.2,3
As HIV treatment is lifelong, it is imperative
that the HCP community keep pushing the boundaries of what constitutes the best that HIV care can offer.

 

HIV Optimized Patient Experience (HOPE) was a market research study conducted in 2016 in the United States by Harris Poll for ViiV Healthcare.1 Data were collected from 2 surveys: 1 conducted with 1501 people living with HIV and 1 conducted with 300 HCPs who treat people living with HIV. Patients and HCPs were not matched. The overarching goal of the study was to understand how patients, and the HCPs who care for them, prioritize treatment goals and how this impacts patient experience with treatment. Surveys were conducted online. Patients were included regardless of treatment status. HCPs were asked to respond to survey questions in the context of their patients who had HIV-1 RNA <50 copies/mL while on stable treatment only. Participants responded to closed-ended questions, most of which were presented on a Likert scale (eg, somewhat agree, strongly agree). Patient data were statistically weighted across several variables using demographic points from the US Centers for Disease Control and Prevention to be representative of the national HIV population. Some percentages presented may have been rounded to the nearest whole number. Survey questions included multiple response choices. Only some of the response choices are shown.1

References: 1. Data on file. ViiV Healthcare group of companies. Research Triangle Park, NC. 2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed May 10, 2017. 3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2nd ed. http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf. Accessed May 10, 2017.

  Selected Patient Populations from The HOPE Study


The definition of a
suboptimized patient:

Current ART user

HIV RNA <50 copies/mL

Have stated dissatisfaction
with current
ART regimen

Current ART user

HIV RNA <50 copies/mL

Have stated satisfaction
with current
ART regimen but noted any of the
quality-of-life statements below

Taking HIV medications
gets in the way of my
lifestyle

I planned my
activities around my
HIV medications so that
side effects do not
interfere with daily
activities (eg, driving,
work, running errands)

I did not take my HIV
medications for one
or more days at a time
to avoid side effects

I changed the type
of foods or the way I
eat
because of my
HIV medications

I missed an important
event, appointment,
or
meeting due to side
effects of my
HIV medications

Of the 1501 patients who
participated in the HOPE Study,


Of the 441 suboptimized patients in the HOPE Study, more than 3 out of 4 responded that they were somewhat or very satisfied with their
current HIV treatment, but noted at least one of these quality-of-life statements, which placed them in the suboptimized group.1

Is there an opportunity to have a deeper conversation with patients who claim to be satisfied with their current HIV treatment?

THE DEFINITION OF A NOT
SUBOPTIMIZED PATIENT:

Current ART user

HIV RNA <50 copies/mL

Have stated satisfaction
with current ART regimen

Have NOT noted any of the
quality-of-life statements above